jemperli - Robuta Search

https://www.medicines.org.uk/emc/product/12669/smpc JEMPERLI 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) -... JEMPERLI 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by GlaxoSmithKline UK 500 mg https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-perla-the-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-in-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer/ GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab)... The PERLA phase II trial is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population. https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced... Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab. us fda breakthrough therapy jemperli dostarlimab receives https://www.thebusinessresearchcompany.com/report/jemperli-dostarlimab-global-market-report Jemperli Dostarlimab Market Share Report 2026, Market Growth To 2035 The Jemperli (Dostarlimab) market is witnessing steady growth over the forecast period, supported by expansion into additional cancer indications, increasing... market share report 2026 jemperli dostarlimab growth https://www.gsk.com/en-gb/media/press-releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/ US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or... Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-jemperli-dostarlimab-gxly-adults-mismatch-repair-deficient FDA D.I.S.C.O. Burst Edition: FDA approvals of Jemperli (dostarlimab-gxly) for adults with mismatch... d i s c o https://www.goodrx.com/compare/jemperli-vs-keytruda Jemperli vs. Keytruda for Uterine Cancer: Important Differences and Potential Risks. Compare Jemperli and Keytruda side effects, costs and risks for treating Uterine Cancer. uterine cancer jemperli vs keytruda https://www.gsk.com/en-gb/media/press-releases/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ US FDA expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary... Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases. https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-file-acceptance-for-jemperli/ GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment... Submission accepted for Priority Review https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-chemotherapy-approved-in-us-for-new-indication/ Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment... Jemperli is the only immuno-oncology treatment approved in a frontline setting for this patient population in combination with chemotherapy in the us